{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:10:44Z","timestamp":1770919844016,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,17]]},"DOI":"10.7759\/cureus.22313","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T10:26:18Z","timestamp":1645093578000},"source":"Crossref","is-referenced-by-count":4,"title":["Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?"],"prefix":"10.7759","author":[{"given":"Lakshmi","family":"Kannan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman M","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, et al.. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007, 2:445-53. 10.2215\/CJN.03531006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al.. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021, 100:753-79. 10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco F","year":"1986","unstructured":"Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986, 29:1215-23. 10.1038\/ki.1986.130","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu D","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al.. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013, 9:10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07002.x","article-title":"Management of minimal lesion glomerulonephritis: evidence-based recommendations","volume":"70","author":"Bargman JM","year":"1999","unstructured":"Bargman JM. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999, 70:3-16. 10.1046\/j.1523-1755.1999.07002.x","journal-title":"Kidney Int Suppl"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw291","article-title":"Con: the use of calcineurin inhibitors in the treatment of lupus nephritis","volume":"31","author":"Nieto MF","year":"2016","unstructured":"Nieto MF, Jayne DR. Con: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016, 31:1567-71. 10.1093\/ndt\/gfw291","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2142","article-title":"Rituximab (Rituxan)","volume":"31","author":"Selewski DT","year":"2010","unstructured":"Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). AJNR Am J Neuroradiol. 2010, 31:1178-80. 10.3174\/ajnr.A2142","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18632%2Foncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio R","year":"2018","unstructured":"Fenoglio R, Sciascia S, Beltrame G, et al.. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018, 9:28799-804. 10.18632%2Foncotarget.25612","journal-title":"Oncotarget"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-013-0672-6","article-title":"The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies","volume":"63","author":"de F\u00e1tima Pereira W","year":"2014","unstructured":"de F\u00e1tima Pereira W, Brito-Melo GE, Guimar\u00e3es FT, Carvalho TG, Mateo EC, Sim\u00f5es e Silva AC. The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies. Inflamm Res. 2014, 63:1-12. 10.1007\/s00011-013-0672-6","journal-title":"Inflamm Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01943-3","article-title":"Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults","volume":"24","author":"Taguchi S","year":"2020","unstructured":"Taguchi S, Ohtake T, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults. Clin Exp Nephrol. 2020, 24:1132-9. 10.1007\/s10157-020-01943-3","journal-title":"Clin Exp Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200401000-00005","article-title":"Cellular responses to protein overload: key event in renal disease progression","volume":"13","author":"Zoja C","year":"2004","unstructured":"Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens. 2004, 13:31-7. 10.1097\/00041552-200401000-00005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi PM","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012, 16:10.1186\/cc11304","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86998-rituximab-for-steroid-dependent-minimal-change-disease-in-adults-is-it-time-for-a-change","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:24Z","timestamp":1707507984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86998-rituximab-for-steroid-dependent-minimal-change-disease-in-adults-is-it-time-for-a-change"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.22313","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}